Breaking Down C4 Therapeutics: 4 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
C4 Therapeutics (NASDAQ:CCCC) has received mixed analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. Analysts have updated their price targets, indicating a significant increase in the average target to $9.75, up 95% from the previous $5.00. The company has shown a strong revenue growth rate of 63.93% as of September 30, 2023, but trails behind its peers in the Health Care sector. Despite a high net margin of -244.19% and impressive ROE and ROA figures, C4 Therapeutics's market capitalization remains below the industry average.
February 26, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
C4 Therapeutics has seen a shift towards neutral analyst ratings, with a significant increase in the average price target to $9.75. The company's strong revenue growth and financial metrics may influence its stock price positively.
The increase in the average price target to $9.75, up 95% from the previous target, indicates a positive outlook from analysts despite the recent shift towards a more neutral stance. The company's strong revenue growth and financial performance metrics, such as ROE and ROA, suggest potential for stock price appreciation. However, its below-average market capitalization in comparison to industry peers may temper expectations.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100